About
We are committed to delivering next-generation cancer therapies.
Coherus Oncology is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. The approval of LOQTORZI® (toripalimab-tpzi) and the advancement of multiple clinical stage immuno-oncology candidates targeting the tumor microenvironment, underscore our commitment to immuno-oncology as a means for providing better treatment outcomes for patients living with cancer.
The approval of LOQTORZI and our diversified pipeline of clinical-stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to advancing immuno-oncology treatments.
Coherus Oncology core values are reflected in each of our employees, who are dedicated, motivated, and passionate about improving patient care. Our leadership team has deep expertise in advancing drugs to market with streamlined regulatory packages. Our colleagues are experts in immunology, oncology, manufacturing and supply chain management and have proven commercial and marketing capabilities.
Coherus has consistently delivered strong execution for over a decade, across multiple disease areas, to successfully develop and commercialize therapies. We are focused on advancing novel immuno-oncology treatments with a strong commitment to patients.
Taking the lead in bringing the next generation immuno-oncology treatments to patients.
